Tag: FAP

Treatment with Onpattro (patisiran) for 1.5 years leads to sustained reductions in disability progression among people with ATTR amyloidosis with cardiomyopathy (ATTR-CM), or damage to the heart. That’s according to interim data from the ongoing open-label extension (OLE) portion of the Phase 3 APOLLO-B clinical trial (NCT03997383). That trial’s initial…

Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to…

Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance of lymph node (LN) fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within the tumor microenvironment (TME). However, the immunomodulatory role of fibroblasts in lymphoma remains unclear. Here, by studying human and mouse DLBCL-LNs, we identify the…

Entry 11146             CDS       T01001                                  Symbol GLMN, FAP, FAP48, FAP68, FKBPAP, GLML, GVM, VMGLOM Name (RefSeq) glomulin, FKBP associated protein   KO K23345   glomulin Organism hsa  Homo sapiens (human) Pathway hsa05131   Shigellosis Network nt06521  NLR signaling   Element N00948   Shigella IpaH7.8 to NLRP3 Inflammasome signaling pathway Disease H00531   Venous malformations Brite KEGG Orthology (KO) [BR:hsa00001] 09160 Human Diseases  09171…

Amvuttra (vutrisiran) and Onpattro (patisiran) showed similar safety and efficacy for familial amyloid polyneuropathy (FAP) patients, according to new analyses from the Phase 3 HELIOS-A trial that supported Amvuttra’s regulatory approval. Both therapies led to similar reductions in transthyretin, the protein that accumulates in FAP, and they were associated with comparable…

Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are being conducted to evaluate the efficacy of CAR-T cells targeting FAP, GPC3, HER2, L1CAM, CEACAM5, MSLN, IL-13RA2, EpCAM, PSMA, and EGFR. Studies have…

More than one year of treatment with eplontersen safely reduced symptoms of nerve damage and improved quality of life for adults with familial amyloid polyneuropathy (FAP), according to top-line data from the Phase 3 NEURO-TTRansform trial. The experimental therapy from Ionis Pharmaceuticals and AstraZeneca also significantly lowered blood levels of…

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues…

Differential expression of complement proteins in the different types of IM To define the transcriptomic profiles of patients with different types of IM, we performed bulk RNAseq on muscle biopsies from 132 IM patients, including those with DM (n = 44), AS (n = 18), IMNM (n = 54), and IBM (n = 16). The DM group included…

Isolation of pure populations of MuSCs and niche cells by fluorescence-activated cell sorting (FACS) Hindlimb muscles were dissected from young (4–6 weeks old) or aged (22–26 months old) C57BL/6J (Jackson Laboratory, 000664) mice and minced until no visible tissue chunks were visible. Muscle was then digested in a 15 ml Falcon…

Mapping molecular changes across malignant transformation We generated single-cell data for 81 samples collected from eight FAP and seven non-FAP donors (Fig. 1a and Supplementary Tables 1 and 2). For each tissue, we performed matched scATAC-seq and snRNA-seq (10x Genomics). We obtained high-quality single-cell chromatin accessibility profiles for 447,829 cells…